IceCure Medical (ICCM) announced the FDA’s Medical Device Advisory Committee Panel’s favorable recommendation with 9 panelists voting in favor and 5 voting against the benefit-risk profile of ...
CAESAREA, Israel, Feb. 15, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that ...
CAESAREA, Israel, March 20, 2019 /PRNewswire/ -- IceCure Medical, developer of the next generation liquid-nitrogen-based cryoablation technology to treat tumors by freezing, today announced promising ...
Conference call to be held today at 10:00 am Eastern Time; Focus on U.S. market for ProSense® in breast cancer indication CAESAREA, Israel, April 3, 2024 /PRNewswire/ -- IceCure Medical Ltd. (ICCM) ...
CAESAREA, Israel, Oct. 3, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration ("FDA") has granted marketing authorization for ProSense®, a minimally invasive cryoablation treatment for patients ...
Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel, March 27, 2025 /PRNewswire/ -- IceCure Medical Ltd. (ICCM) (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback